Cencora Inc

Explore how Cencora’s $3 bn senior note issuance and Goldman Sachs’s stake boost its growth strategy, impact leverage, and create a flexible, long‑term capital base.

Read how Cencora’s new board hire, Ellen G. Cooper, strengthens risk oversight and drives long‑term growth, while routine investor moves keep the stock steady.

Explore why analysts are bullish on Cencora Inc., the impact of board addition Ellen Cooper, and how the firm’s growth, governance and market dynamics shape future value.

Corporate update on Cencora Inc.: Q1 2026 earnings release date disclosed, with Bank of America cutting its price target amid valuation concerns and shifting growth outlook.

Explore Cencora’s rising stock, robust pipeline and cost‑effective therapies, including FDA‑approved Product A, to boost patient outcomes and investor confidence.

Insider sale by Silvana Battaglia at Cencora Inc. reveals market sensitivity; 1.2 M shares sold at $45.30, sparking analyst debate on governance and investor confidence.

Insightful look at Cencora’s recent insider trades and analyst praise, showing how active governance and market positioning shape its health‑care competitiveness.

How Cencora’s $850 m OneOncology deal could boost oncology value‑based contracts, raise ARPP by 7% and add $120 m in annual cash flow while expanding 300 U.S. community sites.

Explore how Cencora’s $5 billion majority stake in OneOncology expands its oncology footprint and positions it for high‑margin growth in the cancer‑treatment market.

Explore Cencora’s FY‑2025 results: revenue up 9.6%, EPS 27% growth, and a 52‑week high driven by oncology and rare‑disease contracts—why investors stay bullish yet watch for next catalysts.